PCRX vs PTCT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

PCRX

45.6
AI Score
VS
PCRX Wins

PTCT

43.0
AI Score

Investment Advisor Scores

PCRX

46score
Recommendation
HOLD

PTCT

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PCRX PTCT Winner
Revenue 546.43M 990.88M PTCT
Net Income 36.09M 28.99M PCRX
Net Margin 6.6% 2.9% PCRX
Operating Income 33.44M 219.05M PTCT
ROE 5.1% -15.2% PCRX
ROA 3.0% 0.9% PCRX
Total Assets 1.20B 3.21B PTCT
Cash 246.96M 508.89M PTCT
Debt/Equity 0.41 -2.80 PTCT
Current Ratio 4.68 3.27 PCRX
Free Cash Flow 125.53M 38.71M PCRX

Relative Price Performance (Last 90 Days)

PCRX 1M: +0.4% · 3M: +57.3% PTCT 1M: +8.3% · 3M: -9.8%

Current Technical Phase

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.9% over 20 days), RSI 82

RSI (14): 81.6 · Price: $36.46

PTCT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 52.2 · Price: $64.91

Fundamentals Snapshot

Metric PCRX PTCT
Market Cap — —
Forward P/E 10.5 20.4
Trailing P/E 39.2 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.7%
Gross Margin 0.8% 0.6%
Operating Margin 0.1% 0.4%
EPS 0.93 -1.47
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.